PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsMyelodysplastic syndromes
MeSH D009190 - myelodysplastic syndromes
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D001855:Bone marrow diseases
$
Success rate
D009190: 
Myelodysplastic syndromes
$
Success rate
D000077428:Gata2 deficiency
0 Companies
0 Drugs
Success rate
D000753:Refractory anemia
$
Success rate
D000756:Sideroblastic anemia
$
Success rate
D006457:Paroxysmal hemoglobinuria
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Novast LaboratoriesDecitabine Decitabine  2019-09-16   
MylanAzacitidine Azacitidine Mylan  2020-03-27   
Lenalidomide Lenalidomide  2022-08-30   
Lenalidomide Lenalidomide Mylan  2020-12-18   
Johnson & JohnsonDecitabine Dacogen  2012-09-20   
CiplaDecitabine Decitabine  2017-11-16   
Lenalidomide Lenalidomide  2022-09-06   
Lupin ResearchDecitabine Decitabine  2018-11-09   
SandozDecitabine Decitabine  2014-08-28   
Dr Reddys LaboratoriesDecitabine Decitabine  2013-07-11   
Lenalidomide Lenalidomide  2021-10-14   
Zydus TherapeuticsDecitabine Decitabine  2021-11-19   
Lenalidomide Lenalidomide  2022-09-12   
Sun Pharmaceutical IndustriesDecitabine Decitabine  2014-01-28   
Lenalidomide Lenalidomide  2023-02-08   
ApotexLenalidomide Lenalidomide  2022-08-30   
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
75%
187/248
Phase 2
35%
90/255
Phase 3
21%
26/122
Approved: 5Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Johnson & Johnson
1
2
3
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use